You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaNervous SystemProduct ClassPsychoanalepticsPharmacological SubgroupAnti-Dementia DrugsChemical SubgroupAnticholinesterasesCondition StudiedAlzheimer Disease
Sponsor Protocol NumberGAL-USA-1Enrollment636Data PartnerJohnson & Johnson% Female62.0%Mean/Median Age (Years)75.7% White91.0%
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2025-0796 : Evaluating and Benchmarking the Use of Generated-Clinical Data for Alzheimer’s Disease Trials: a Retrospective Study.
- 2025-0352 : ALL-EMBRACED: clinicAL triaLs web-sErvice to Modify eligiBility cRiteria and pre-screening viA artifiCial intElligence methoDs
- 2024-0840 : Sex differences in the efficacy and adverse events of anti-dementia medication in Alzheimer’s disease: a systematic review
- 2022-5053 : Adverse events reported in association with APOE genotype during clinical trials
- 2021-4836 : Adverse events of acetylcholinesterase inhibitors - systematic review and meta-analysis of double-blind randomized controlled trials
- 2016-0765 : Improving the statistical analysis of cognitive outcomes in randomised controlled trials: The 'Optimising the Analysis of Cognition' Collaboration
- 2015-0592 : Detection of uninformative clinics during the trial of a new drug using statistical and machine learning techniques